CREB3L4 as A Potential Drug Target Or Biomarker for Various Diseases

Target Name: CREB3L4

NCBI ID: G148327

CREB3L4

CREB3L4 as A Potential Drug Target Or Biomarker for Various Diseases

CREB3L4 (Tisp40) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and metabolic diseases. CREB3L4 is a gene that encodes a protein known as Tisp40, which is a key regulator of the CREB3 complex, a protein that plays a crucial role in the regulation of gene expression and cell behavior.

The CREB3 complex is a protein-protein interaction network that is involved in a wide range of cellular processes, including stress response, DNA replication, and metabolism. The CREB3 complex is composed of several subunits, includingCREB3, p100, and p101, which are involved in the regulation of gene expression and the establishment of a transcription origin. Tisp40 is a key regulator of the CREB3 complex, and it is involved in the regulation of various cellular processes, including the translation of RNA into protein, the establishment of DNA repair pathways, and the regulation of cell growth and differentiation.

CREB3L4 is a gene that has been shown to be involved in a wide range of diseases, including cancer, neurodegenerative disorders, and metabolic diseases. For example, studies have shown that high levels of CREB3L4 are associated with an increased risk of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, high levels of CREB3L4 have been shown to be associated with an increased risk of cancer, including breast and ovarian cancer.

In addition to its potential as a drug target or biomarker, CREB3L4 is also a promising target for research into the regulation of gene expression and the development of new therapies. For example, researchers have been interested in studying the mechanisms underlying the regulation ofCREB3L4 by various factors, including drugs and cellular stressors. Additionally, researchers have been interested in studying the consequences of disrupting CREB3L4 activity for the regulation of cellular processes, including the translation of RNA into protein, DNA repair, and cell growth.

In conclusion, CREB3L4 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases. Its involvement in the regulation of the CREB3 complex and its association with a wide range of diseases make it an attractive target for research into the mechanisms underlying its regulation and the development of new therapies. Further research is needed to fully understand the role of CREB3L4 in cellular processes and its potential as a drug target or biomarker.

Protein Name: CAMP Responsive Element Binding Protein 3 Like 4

Functions: Transcriptional activator that may play a role in the unfolded protein response. Binds to the UPR element (UPRE) but not to CRE element. Preferentially binds DNA with to the consensus sequence 5'-T[GT]ACGT[GA][GT]-3' and has transcriptional activation activity from UPRE. Binds to NF-kappa-B site and has transcriptional activation activity from NF-kappa-B-containing regulatory elements (By similarity)

The "CREB3L4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREB3L4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets